Share on LinkedInShare on LinkedIn

ARTICLE · 02 JUNE 2015

Product Hopping And Antitrust: Mylan Court Dismisses Claims On Summary Judgment, Citing Need To Avoid Chilling Pharmaceutical Innovation

BakerHostetler
BakerHostetler
Contributor
BakerHostetler

BakerHostetler

Recognized as an innovator and one of the top firms for client service, BakerHostetler helps...

View firm profile
Explore more from BakerHostetler

A recent summary judgment opinion from the Eastern District of Pennsylvania breaks new ground in the developing antitrust law on "product hopping" claims.

United StatesAntitrust/Competition Law

A recent summary judgment opinion from the Eastern District of Pennsylvania breaks new ground in the developing antitrust law on "product hopping" claims. "Product hopping" refers to the practice of changing the form or dosage of a branded drug without changing its underlying composition. Though drug manufacturers often make such changes for legitimate business reasons, they may also – thanks to the vagaries of the Hatch-Waxman Act and the Food and Drug Administration's (FDA) approval processes – have the effect of preventing a generic competitor from entering the market as soon as it otherwise could have.

Back in February, this blog explained this dynamic and the resulting antitrust concerns about product hopping by branded drug manufacturers. We also surveyed the cases that had addressed such claims up to that time, noting that the only reported decisions were from district courts in the context of a motion to dismiss. With District Judge Paul Diamond's April 16

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from